European Society of Cardiology (ESC) Congress highlights need
for transcatheter tricuspid valve treatment options
LONDON & TEWKSBURY, Mass.–(BUSINESS WIRE)–Mitralign shared early experience with its Percutaneous Tricuspid Valve
Annuloplasty System (PTVAS) designed to treat tricuspid regurgitation
(TR) in a September 1 symposium at the European Society of Cardiology
(ESC) Congress in London this week. The company continues
to raise awareness of emerging treatment options for TR based
on outcomes reported from compassionate use cases utilizing its PTVAS.
“The heart failure community continues to see patients with tricuspid
regurgitation and we have very limited treatment options after medical
therapy,” commented Stefan D. Anker, MD Professor of Innovative Clinical
Trials, University Medicine, Göttingen Germany and co-chair of the a
symposium. “The emergence of innovations such
as the Mitralign PTVAS means we may soon
have a percutaneous repair option for tricuspid regurgitation rather
than traditional surgery.”
The symposium “Tricuspid Regurgitation in the Heart Failure Population:
How to Treat It” was co- chaired by Anker and Gerasimos Filippatos, MD,
Athens, Greece and reviewed both surgical and transcatheter approaches
for the treatment of TR. Prof. Dr. med. J. Schofer, Hamburg, Germany
and Azeem Latib, MD, Milan, Italy presented case reviews and information
on compassionate use cases using Mitralign’s Percutaneous Tricuspid
Valve Annuloplasty System (PTVAS).
“We have seen very encouraging results treating tricuspid regurgitation
using our platform and, similar to our United States tricuspid
IDE, we are planning to commence a European CE study in the coming
months,” stated Rick Geoffrion, chief executive officer of Mitralign.
Mitralign is the only company to provide physicians with the tools they
need to perform minimally invasive, percutaneous procedures for both
functional mitral regurgitation and tricuspid regurgitation.
Both systems utilize the same innovative platform. The Mitralign
Percutaneous Annuloplasty System (MPAS) is expected to receive CE mark
approval for treatment of functional mitral regurgitation (FMR) in
2015. Currently, Mitralign’s Percutaneous Tricuspid Valve Annuloplasty
System (PTVAS) and Percutaneous Annuloplasty System (MPAS) are under
clinical investigation and not available for sale or distribution.
Additional information on both the PTVAS and the MPAS will be
presented in 2015 at PCR London Valves, September 20-22 in
Berlin and during TCT in San Francisco, October 11-15.
About Tricuspid Regurgitation (TR) Tricuspid regurgitation occurs
when the tricuspid valve fails to open and close properly, causing blood
to flow backwards into the right atrium. If left untreated, TR can lead
to heart enlargement and heart failure. In the U.S. alone, there are an
estimated 1.6 million patients suffering from TR.1 It is
estimated that 50% of patients with mitral regurgitation have moderate
to severe tricuspid regurgitation.2 TR is currently
undertreated by surgery. In the U.S. surgeons treat only 5,500 patients
per year, most of them in conjunction with left heart surgeries. When
treating the valves, surgeons choose repair 90% of the time versus
About Mitralign Inc.
Mitralign Inc. is the valve repair
company with the only direct transcatheter annuloplasty system designed
to treat both functional mitral regurgitation and functional tricuspid
regurgitation. The company is a venture-backed, medical innovation
company located near Boston, Massachusetts, USA. For more information,
1. Stuge O., Liddicoat J., et al. JTCS 2006;132:1258-61
et al. Circ Cardiovasc Interv 2009;2:565-573
3. Rogers JH.
Circulation 2009:119: 2718-25
David Schleifer, 617-869-6166